Metabolic Dysfunction in New‐Onset Idiopathic Intracranial Hypertension: Identification of Novel Biomarkers

Johanne Juhl Korsbæk,Rigmor Højland Jensen,Dagmar Beier,Elisabeth Arnberg Wibroe,Snorre Malm Hagen,Laleh Dehghani Molander,Matthew Paul Gillum,Katrine Svart,Thomas Folkmann Hansen,Lisette J.A. Kogelman,Connar Stanley James Westgate
DOI: https://doi.org/10.1002/ana.27010
IF: 11.2
2024-06-24
Annals of Neurology
Abstract:Objective Idiopathic intracranial hypertension (IIH) is a neurometabolic disease with an increasing incidence. The pathophysiology is unknown, but improvement of diagnosis and management requires discovery of novel biomarkers. Our objective was to identify such candidate biomarkers in IIH, and secondarily, test for associations between identified metabolites and disease severity. Methods This is a prospective case–control study with collection of cerebrospinal fluid (CSF), serum, and clinical data from new‐onset, treatment‐naïve patients with IIH (n = 60). Patients were included consecutively from 2 tertiary headache centers in Denmark, and age, sex, and body mass index (BMI) ‐matched healthy controls (n = 35) were recruited. Clinical data were retrieved at ocular remission (n = 55). Samples were analyzed using non‐targeted mass spectrometry. Results Serum sphingosine 1‐phosphate (S1P), adenosine, and glutamate were 0.46‐fold (q
neurosciences,clinical neurology
What problem does this paper attempt to address?